Suprelorin F
Loading...Suprelorin F Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
KEEP OUT OF REACH OF CHILDREN. DO NOT HANDLE THIS PRODUCT IF YOU ARE PREGNANT OR NURSING OR SUSPECT YOU MAY BE PREGNANT. Accidental administration may lead to a disruption of the menstrual cycle. Avoid direct skin contact with the implant; if skin contact occurs, wash the affected area immediately with soap and water. The use of gloves is advised. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using Suprelorin® F (4.7 mg) Implant to prevent accidental injection. In case of accidental human injection, a physician should be consulted and the implant should be removed.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Suprelorin® F (4.7 mg) Implant is indicated for the management of adrenal gland cortical disease in the male and female domestic ferret.
History
There is currently no drug history available for this drug.
Other Information
Suprelorin® F (4.7 mg) Implant is a synthetic GnRH analogue (deslorelin acetate) in a biocompatible, slow release subcutaneous implant. The implant is a solid, opaque, white to pale yellow cylinder, 2.3 mm × 12.5 mm in length and weighing 50 mg. The Suprelorin® F (4.7 mg) Implant comes pre-loaded in an implanting needle. Each implant contains 4.7 mg deslorelin (as deslorelin acetate) in an inert matrix.
Chemical Structure – Deslorelin Acetate
[(6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide]GnRH
Sources
Suprelorin F Manufacturers
-
Virbac Ah, Inc.
![Suprelorin F (Deslorelin Acetate) Implant [Virbac Ah, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Suprelorin F | Virbac Ah, Inc.
The recommended dosage is one, 4.7 mg implant per ferret every 12 months. Appropriate clinical monitoring is suggested to determine that the symptoms of adrenal gland disease are being adequately controlled.
Do not use if the foil pouch is damaged.
Remove the luer lock cap from the implanting needle. Attach the actuator syringe to the implanting needle using the luer lock connection. One implant should be implanted subcutaneously at the dorsal aspect of the base of the neck. Administer only one implant per ferret. Select the implant site by locating the area of the back midway between the shoulder blades. It is not necessary to prepare the implantation site. If the hair is long, a small section may be clipped if required. Lift the loose skin between the shoulder blades. Insert the entire length of the needle subcutaneously. Fully depress the actuator syringe plunger. Press the skin at the insertion site as the needle is slowly withdrawn, and maintain pressure for 30 seconds. Examine the implanting needle to verify that the implant has not remained within the needle, and that the blue plastic spacer is visible at the tip of the needle. It may be possible to palpate the implant in situ. The biocompatible implant does not require removal. Wash hands after use.
Repeat treatment every 12 months to maintain efficacy. Appropriate endocrine testing and clinical monitoring should be performed at appropriate intervals to monitor the response to therapy.
Login To Your Free Account